Constructing J-aggregates of cyanine dye for NIR-II in vivo dynamic vascular imaging and long-term targeting of tumors
Jiaqi Zhou, Hao Li, Huijun Li, Jiayi Ding, Zhong Du, Jiabao Xiong, Hongyang Yao, Xueliang Zhang, Nuernisha Alifu, Biao Dong
Abstract
Cyanine molecules with the second near-infrared (NIR-II) emission hold great potential for bioimaging owing to their great biocompatibility, but the scissor-like structure of these molecules poses a major bottleneck in obtaining efficient NIR-II fluorescence probes. Constructing J-aggregates represents a promising strategy for obtaining biomedical NIR-II emissive materials. However, achieving J-aggregates in cyanine dyes with large torsion angles between the heterocyclic rings poses a challenge. In this study, we introduced the guanidine of tumor molecular targeted peptide 1 (TMTP1) to increase steric hindrance of IR-783 and reduce the angle of IR-783 scissors. The near-coplanar structure of IR-783@peptide TMTP1 composite facilitates the formation of a novel J-aggregates (IR-783-LP-TMTP1) with super-stable effect for NIR-II in vivo dynamic vascular imaging and remarkable tumor targeting capability. The stable emission wavelength and high spatial resolution of J-aggregates was demonstrated for brain and ear vasculature bioimaging under 808 nm laser excitation. Additionally, J-aggregates exhibits robust tumor-targeting capability towards cervical tumors, indicating their potential in cervical cancer diagnosis. This work develops a molecular design strategy to construct bright NIR-II J-aggregates with super-stable and robust tumor-targeting properties and paving the way for improving bioimaging performance of similar molecules. We introduced the guanidine of tumor molecular targeted peptide 1 (TMTP1) to increase steric hindrance of IR-783 and reduce the angle of IR-783 scissors. The near-coplanar structure of IR-783@peptide TMTP1 composite facilitates the formation of a novel J-aggregates (IR-783-LP-TMTP1) with super-stable effect for NIR-II in vivo dynamic vascular imaging and remarkable tumor targeting capability.